Skip to main content
Premium Trial:

Request an Annual Quote

Genewiz, BeiGene Collaborate on Cancer Biomarker Discovery

NEW YORK (GenomeWeb News) – Genewiz today announced a deal with BeiGene for the use of Genewiz's cancer panels to accelerate cancer biomarker discovery.

Under the terms of the deal, Beijing-based BeiGene will use Genewiz's OncoGxOne Discovery cancer panels to identify and elucidate genetic variations in cancers that are prevalent in China and the Asia-Pacific region.

Financial and other terms of the deal were not disclosed.

"Our collaboration with Genewiz and application of the OncoGxOne(TM) cancer panels will enable characterization of primary tumor models at the genetic level, with a focus on aberrations in cancer related genes," Lai Wang, head of Discovery Biomarkers for BeiGene, said in a statement. BeiGene is a life science biotech firm focused on developing oncology drugs.

The deal is the second by South Plainfield, N.J.-based Genewiz in recent weeks aimed at the Chinese market. In late June it and KeyTest Diagnostics announced a collaboration to develop molecular diagnostics for that market.

Also, Genewiz and the John Theurer Cancer Center at Hackensack University Medical Center last month said they were collaborating on discovering ovarian cancer biomarkers.